220 related articles for article (PubMed ID: 27409073)
1. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.
Mason C; Savona S; Rini JN; Castillo JJ; Xu L; Hunter ZR; Treon SP; Allen SL
Br J Haematol; 2017 Oct; 179(2):339-341. PubMed ID: 27409073
[No Abstract] [Full Text] [Related]
2. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Hartsell L; Janes A; Larck C; Park S; Arnall JR
J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
[TBL] [Abstract][Full Text] [Related]
3. Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Plander M; Szendrei T; Vadvári Á; Iványi J
Pathol Oncol Res; 2020 Jan; 26(1):591-592. PubMed ID: 30357751
[No Abstract] [Full Text] [Related]
4. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C
Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870
[No Abstract] [Full Text] [Related]
5. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Treon SP
Haematologica; 2018 Jul; 103(7):e307-e310. PubMed ID: 29472352
[No Abstract] [Full Text] [Related]
6. Rare case of Bing-Neel syndrome treated successfully with ibrutinib.
Hashmi H; Dhanoa JS; Emmons R
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31243026
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
8. Bing-Neel syndrome: A case reports.
Demircioğlu S; Oltulu P; Emlik GD; Tekinalp A; Çeneli Ö
J Oncol Pharm Pract; 2021 Oct; 27(7):1758-1761. PubMed ID: 33356992
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
Tucker DL; Naylor G; Kruger A; Hamilton MS; Follows G; Rule SA
Br J Haematol; 2017 Jul; 178(2):327-329. PubMed ID: 27197509
[No Abstract] [Full Text] [Related]
10. Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
Vitagliano O; Trastulli F; Cacace F; Leone S; Memoli M; Scalia G; Notarangelo M; Mainolfi CG; De Renzo A; Pane F
Leuk Lymphoma; 2018 Jul; 59(7):1734-1737. PubMed ID: 29019439
[No Abstract] [Full Text] [Related]
11. Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.
Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
Leuk Lymphoma; 2018 Nov; 59(11):2746-2748. PubMed ID: 29569974
[No Abstract] [Full Text] [Related]
12. Bing-Neel syndrome: a rare complication of Waldenström macroglobulinemia.
Sánchez-Guerrero S; Castillo JJ
Blood; 2015 Sep; 126(11):1390. PubMed ID: 26605390
[No Abstract] [Full Text] [Related]
13. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
Castillo JJ; D'Sa S; Lunn MP; Minnema MC; Tedeschi A; Lansigan F; Palomba ML; Varettoni M; Garcia-Sanz R; Nayak L; Lee EQ; Rinne ML; Norden AD; Ghobrial IM; Treon SP
Br J Haematol; 2016 Mar; 172(5):709-15. PubMed ID: 26686858
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.
Varettoni M; Marchioni E; Bonfichi M; Picchiecchio A; Arcaini L; Arbasino C; Gotti M; Da Vià M; Delmonte M; Sciarra R; Cazzola M
Am J Hematol; 2015 Aug; 90(8):E152-3. PubMed ID: 25975811
[No Abstract] [Full Text] [Related]
15. Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
Jafri H; Khan I; Sidda A; Khan NAJ; Kheetan M; Griswold D; Pacioles T
J Investig Med High Impact Case Rep; 2021; 9():23247096211021228. PubMed ID: 34078157
[TBL] [Abstract][Full Text] [Related]
16. How we manage Bing-Neel syndrome.
Castillo JJ; Treon SP
Br J Haematol; 2019 Nov; 187(3):277-285. PubMed ID: 31430829
[TBL] [Abstract][Full Text] [Related]
17. Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).
Simon L; Fitsiori A; Lemal R; Dupuis J; Carpentier B; Boudin L; Corby A; Aurran-Schleinitz T; Gastaud L; Talbot A; Leprêtre S; Mahe B; Payet C; Soussain C; Bonnet C; Vincent L; Lissandre S; Herbrecht R; Kremer S; Leblond V; Fornecker LM
Haematologica; 2015 Dec; 100(12):1587-94. PubMed ID: 26385211
[TBL] [Abstract][Full Text] [Related]
18. Bing-Neel Syndrome Successfully Treated with Tirabrutinib.
Oyama T; Taoka K; Chiba A; Matsuda K; Maki H; Masamoto Y; Kurokawa M
Intern Med; 2022 Dec; 61(23):3575-3579. PubMed ID: 35569989
[TBL] [Abstract][Full Text] [Related]
19. Bing-Neel syndrome with a paravertebral mass.
Suzuki D; Sato D; Kikuchi K; Suzuki T; Sugasawa K; Saito S; Uchimura F; Suzuki Y
Am J Med Sci; 2023 Oct; 366(4):316-320. PubMed ID: 37473959
[TBL] [Abstract][Full Text] [Related]
20. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
Furman RR; Luan Y; Bilotti E; Graef T
Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
